^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:everolimus (mTOR inhibitor) +
    xentuzumab (BI-836845) (IGF-2 inhibitor, IGF1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast Cancer Res
    Title:

    A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

    Published date:
    01/15/2021
    Excerpt:
    Patients with hormone receptor-positive/HER2-negative LA/MBC resistant to non-steroidal aromatase inhibitors were enrolled....In a pre-specified subgroup of patients without visceral metastases at screening, xentuzumab/everolimus/exemestane showed evidence of PFS benefit versus everolimus/exemestane (hazard ratio 0.21 [0.05-0.98]; P = 0.0293).
    Secondary therapy:
    exemestane
    DOI:
    10.1186/s13058-020-01382-8.